This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
COMMIT-CCS-2 was a randomized, double-blind, factorial phase 4 trial evaluating clopidogrel and metoprolol in acute myocardial infarction. The registry reports enrollment of 46000 participants and identifies death and a composite outcome of death, non-fatal reinfarction or stroke as the primary endpoint.
| Feature | COMMIT-CCS-2 |
|---|---|
| Phase | Phase 4 |
| Condition | Acute Myocardial Infarction |
| Design | Randomized, double-blind, factorial |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Interventions | Clopidogrel and metoprolol |
| Enrollment | 46000 |
| Status | Completed |
| Lead sponsor | University of Oxford |
| Sponsor type | Other |
| ClinicalTrials.gov | NCT00222573 |
2. Clinical Question
The registry describes COMMIT-CCS-2 as a factorial randomized trial evaluating the efficacy and safety of adding clopidogrel to aspirin or using metoprolol in myocardial infarction. The registered condition is acute myocardial infarction, and the interventions identified in the record are clopidogrel and metoprolol.
Population
Participants with acute myocardial infarction.
Interventions
Clopidogrel and metoprolol are identified as the trial interventions.
Design question
The factorial structure permits randomized evaluation of interventions within the same overall trial framework.
Primary question
The registered primary endpoint concerns death and the composite outcome of death, non-fatal reinfarction or stroke.
3. Trial Design
The registry identifies the allocation as randomized, the design model as factorial, and the masking as double. These three features define the central statistical structure of the study: treatment assignment is randomized, more than one intervention is evaluated within the factorial framework, and the trial is double-blind.
Randomization is the foundation for comparing outcomes across assigned treatment groups while reducing systematic differences in measured and unmeasured baseline characteristics.
A factorial trial evaluates multiple interventions within a common randomized framework rather than requiring separate trials for each intervention.
The registry classifies the study as double-blind, reducing the potential for knowledge of treatment assignment to influence trial conduct and outcome assessment.
The registry identifies treatment as the study's primary purpose.
4. Factorial Structure and Statistical Interpretation
The most important design feature of COMMIT-CCS-2 is its factorial structure. In a factorial trial, multiple interventions can be randomized within the same study population. This allows the statistical analysis to estimate the effects associated with the different intervention factors while using the same broad trial infrastructure.
For a two-factor factorial design, the conceptual structure can be represented as:
The interaction term represents whether the effect of one intervention differs according to the level of the other intervention. Whether an interaction was formally specified or tested in COMMIT-CCS-2 is not reported in the registry information available here.
The distinction between a main effect and an interaction is essential. A main effect asks whether an intervention is associated with a difference in the endpoint across its randomized levels, averaging over the other factor when appropriate. An interaction asks a different question: whether the effect of one factor changes depending on the other factor.
5. Primary Endpoints
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Death | Death | The registry does not report a specific time frame in the information available here. |
| Composite outcome | Death, non-fatal reinfarction or stroke | The registry does not report a specific time frame in the information available here. |
The primary endpoint entry combines two related but distinct outcomes: death considered on its own, and a composite consisting of death, non-fatal reinfarction or stroke. These outcomes should be kept analytically separate because a treatment effect on the composite can be driven by one component more strongly than by another.
6. Planned Analysis
The registry does not post statistical analyses or numerical efficacy results for the primary endpoints. The appropriate analysis therefore begins with the endpoint structure and the factorial randomized design rather than an outcome estimate.
Death as a time-to-event endpoint
For a randomized trial in which death is assessed over follow-up, a standard approach is to compare time to death between randomized treatment groups using survival-analysis methods. Kaplan-Meier estimation can describe the event-time distribution, while a log-rank test can compare groups and a Cox proportional-hazards model can estimate a hazard ratio with a confidence interval.
The key statistical advantage of time-to-event analysis is that it can incorporate different lengths of follow-up and right-censoring. A participant who has not experienced death by the end of available follow-up can still contribute information before censoring.
Composite outcome
The composite endpoint of death, non-fatal reinfarction or stroke is also naturally analyzed as a time-to-first-event outcome when the endpoint is defined by the first occurrence of any component. A standard analysis compares time to the first qualifying component between randomized groups.
Interpretation should also examine the individual components. A statistically detectable difference in a composite does not establish that every component changed to the same extent. Conversely, the absence of a reported component-specific estimate prevents a component-level interpretation.
Factorial analysis
For a factorial design, the primary model should reflect the randomized factors. Main effects can be estimated within the factorial framework, while an interaction term can be used when the scientific question concerns whether one intervention's effect depends on the other intervention.
Here βA represents the main effect of factor A, βB the main effect of factor B, and βAB the interaction between the two factors. The equation is a general teaching representation of factorial analysis, not a reconstruction of an unreported COMMIT-CCS-2 statistical model.
7. Statistical Methodology
Randomization
Randomization creates the principal basis for causal comparison. Because treatment assignment is randomized, differences in outcomes between assigned groups can be interpreted within the randomized trial framework rather than as simple observational associations.
Factorial design
The factorial model is designed to evaluate more than one intervention within a shared randomized trial. Its efficiency comes from allowing the interventions to be studied simultaneously, provided the statistical assumptions and prespecified analysis are appropriate.
Time-to-event analysis
Both registered primary endpoints are event-based outcomes. For this type of endpoint, survival methods are generally preferable to simply comparing the proportion of participants who experience an event without accounting for follow-up time.
The Kaplan-Meier estimator uses the number of events and the number at risk at each event time to estimate the probability of remaining event-free over time.
Hazard ratios
A Cox proportional-hazards model is commonly used to estimate a hazard ratio for a time-to-event endpoint. A hazard ratio below 1 indicates a lower estimated instantaneous event rate in one group relative to the reference group, whereas a value above 1 indicates a higher estimated instantaneous event rate.
A hazard ratio would describe a relative event rate over follow-up under the fitted model. It would not directly represent an absolute risk difference, the percentage of participants benefiting, or the probability that a particular individual will experience an event.
A confidence interval would quantify statistical uncertainty around the estimated hazard ratio. The p-value, if reported, would address evidence against a specified null hypothesis; it would not measure the size or clinical importance of the effect.
Composite endpoints
A composite endpoint combines multiple clinically distinct events into a single outcome. This can increase the number of observed events and may improve statistical efficiency, but it also creates an interpretation requirement: the components should be considered individually rather than assuming that the composite represents a uniform clinical effect.
8. Statistical Methods Explained
Why use a factorial design?
A factorial design allows multiple interventions to be evaluated within one randomized study. Rather than treating each intervention as requiring an entirely separate trial, the design can use a common study population and common trial infrastructure. This can make efficient use of participants when the factorial assumptions are appropriate.
What is a main effect?
A main effect describes the average effect associated with one randomized factor across the levels of another factor. In a factorial analysis, this provides an overall estimate for an intervention while accounting for the other factor in the design.
What is an interaction?
An interaction occurs when the effect of one intervention differs according to the level of another intervention. For example, if the effect of factor A were different when factor B was present versus absent, that pattern would constitute statistical interaction.
Why does interaction matter in a factorial trial?
If the two intervention effects interact substantially, a single main-effect estimate can obscure the treatment pattern in individual factorial cells. The interpretation then needs to focus on the joint treatment combinations and the interaction rather than assuming that the two effects simply add together.
Why analyze death separately from the composite endpoint?
The composite endpoint contains death, non-fatal reinfarction and stroke. A composite can provide a broader measure of clinical events, but the individual components may differ in frequency, severity and treatment responsiveness. Death therefore answers a narrower question than the composite and should be interpreted independently.
Why use time-to-event methods?
When participants can be followed for different lengths of time, time-to-event methods use information about when events occur and can appropriately account for participants who remain event-free at the end of observation. This is different from treating all participants as if they had exactly the same follow-up duration.
9. Confidence Intervals and P-Values
No numerical estimates, confidence intervals or p-values are posted in the registry information for the primary endpoints. Nevertheless, these quantities have distinct roles in a statistical analysis of a randomized trial.
Effect estimate
The effect estimate describes the magnitude and direction of the treatment comparison, such as a hazard ratio for a time-to-event endpoint.
Confidence interval
The confidence interval describes statistical uncertainty around the estimated treatment effect under the specified analysis framework.
P-value
A p-value evaluates compatibility with a null hypothesis under the statistical model. It does not measure effect size or clinical importance.
Absolute effects
Absolute event risks and risk differences answer different questions from relative measures and are useful when available.
10. Analysis of the Composite Endpoint
The registered composite outcome is defined as death, non-fatal reinfarction or stroke. The statistical analysis of such an endpoint normally treats the first qualifying event as the primary event for the composite time-to-event analysis.
| Component | Role in registered endpoint | Statistical consideration |
|---|---|---|
| Death | Component of the composite | Also registered separately as a primary endpoint. |
| Non-fatal reinfarction | Component of the composite | Would contribute an event when it is the first qualifying component. |
| Stroke | Component of the composite | Would contribute an event when it is the first qualifying component. |
One important issue with composite endpoints is component weighting. If one component occurs much more frequently than another, the overall composite result can be driven predominantly by that component. A complete statistical interpretation therefore considers the composite and its individual components together when component-specific results are available.
11. Double-Blind Randomized Design
The registry identifies COMMIT-CCS-2 as both randomized and double-blind. These design characteristics address different sources of bias.
Blinding does not replace randomization, and randomization does not eliminate every possible source of bias. They address different parts of the trial's internal validity.
12. Trial Timeline
Trial start
The registry lists the study start date as 1999-07.
Randomized factorial trial
The registry identifies randomized allocation, a factorial design model and double masking.
46000 participants
The registry reports an enrollment of 46000.
Completed
The ClinicalTrials.gov record lists the study status as completed.
13. Limitations
- No posted statistical analyses: The registry does not provide numerical statistical analyses for the registered primary endpoints.
- No reported endpoint time frame: The registry information available here identifies the primary endpoints but does not specify their time frame.
- No numerical effect estimates: Hazard ratios, risk differences, confidence intervals and p-values are not reported in the registry information available here.
- No component-specific results: The registry information does not provide separate numerical results for death, non-fatal reinfarction or stroke.
- Factorial interaction: The registry identifies a factorial design but does not report the statistical treatment of interaction between the intervention factors.
- Analysis details: The registry information does not specify the exact statistical model, analysis population, censoring rules or missing-data approach used for the primary endpoints.
14. Why This Trial Matters Statistically
COMMIT-CCS-2 is a useful teaching case because its factorial design illustrates a central principle of efficient randomized-trial methodology: multiple interventions can be evaluated within a common experimental framework. The design also provides a natural setting for distinguishing main effects from interactions and for understanding why composite clinical endpoints require careful interpretation.
| Concept | How it appears in COMMIT-CCS-2 |
|---|---|
| Randomization | The registry identifies randomized allocation. |
| Factorial design | The registry identifies the design model as factorial. |
| Double-blind design | The registry identifies the masking as double. |
| Multiple interventions | Clopidogrel and metoprolol are identified as interventions. |
| Time-to-event analysis | Death and the composite clinical-event endpoint are naturally suited to time-to-event methods. |
| Composite endpoint | The primary composite consists of death, non-fatal reinfarction or stroke. |
| Component interpretation | The composite and its individual clinical components answer related but distinct questions. |
| Interaction | The factorial structure creates a potential statistical question about whether intervention effects depend on one another. |
15. Related Tutorials
Learn more about the methods used in this trial:
16. Related Calculators
17. Sources
- ClinicalTrials.gov: NCT00222573 — COMMIT-CCS-2.
Continue through the Clinical Biostats library
Explore statistical tutorials and calculators that explain randomized trial design and the methods used to analyze clinical endpoints.
18. Record Summary
COMMIT-CCS-2 is a completed phase 4, randomized, double-blind factorial trial with enrollment of 46000 participants. The registry identifies acute myocardial infarction as the condition, clopidogrel and metoprolol as interventions, and death plus the composite outcome of death, non-fatal reinfarction or stroke as the primary endpoint. Statistically, the trial is particularly useful for understanding how factorial randomization can evaluate multiple interventions within one study and how main effects, interactions, time-to-event methods and composite endpoints should be distinguished.